Mr Jon Stobo

  • Biostatistician (Clinical Trials Research)

telephone: 01412113813
email: Jon.Stobo@glasgow.ac.uk

CRUK CTU Glasgow, Statistics Office (Room G/22), Admin Building, Gartnavel Royal Hospital, 1055 Great Western Road, Glasgow, G12 0XH

ORCID iDhttps://orcid.org/0000-0003-4829-7440

Publications

List by: Type | Date

Jump to: 2020 | 2018 | 2017 | 2016 | 2015 | 2013
Number of items: 11.

2020

Horne, G. et al. (2020) A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia, 34(7), pp. 1775-1786. (doi: 10.1038/s41375-019-0700-9) (PMID:31925317) (PMCID:PMC7224085)

2018

Ashton, M. et al. (2018) SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma. Clinical and Translational Radiation Oncology, 8, pp. 45-49. (doi: 10.1016/j.ctro.2017.11.004)

Fulton, B. et al. (2018) PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. Clinical and Translational Radiation Oncology, 8, pp. 12-16. (doi: 10.1016/j.ctro.2017.11.003)

2017

Paul, J. , Kelly, C. , Stobo, J. and Powles, T. (2017) Reply to M. Horiguchi et al. Journal of Clinical Oncology, 35(29), pp. 3373-3374. (doi: 10.1200/jco.2017.74.4292) (PMID:28800270)

Jones, R. J. et al. (2017) Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer. Journal of Clinical Oncology, 35(16), pp. 1770-1777. (doi: 10.1200/JCO.2016.70.7828) (PMID:28402747)

Goranova, T. et al. (2017) Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium. British Journal of Cancer, 116, pp. 1294-1301. (doi: 10.1038/bjc.2017.86) (PMID:28359078) (PMCID:PMC5482731)

2016

MacLeod, N., Kelly, C. , Stobo, J. , McMahon, L., Taggart, D., Fallon, M. and Laird, B. J. (2016) Pain in malignant pleural mesothelioma: a prospective characterization study. Pain Medicine, 17(11), pp. 2119-2126. (doi: 10.1093/pm/pnw061) (PMID:27117437)

2015

Mac Leod, N. et al. (2015) F-18 FDG PET-CT influences target delineation when combined with standard CT-based radiotherapy planning in the palliative setting in malignant pleural mesothelioma; an exploratory study. Reports of Radiotherapy and Oncology, 2(2), e3999. (doi: 10.17795/rro-3999)

MacLeod, N. et al. (2015) Is radiotherapy useful for treating pain in mesothelioma?: a phase II trial. Journal of Thoracic Oncology, 10(6), pp. 944-950. (doi: 10.1097/JTO.0000000000000499) (PMID:25654216)

2013

Gallipoli, P. et al. (2013) Safety and efficacy of pulsed imatinib with or without G-CSFversuscontinuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. British Journal of Haematology, 163(5), pp. 674-676. (doi: 10.1111/bjh.12532)

Chen, M. et al. (2013) Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. Journal of the National Cancer Institute, 105(6), pp. 405-423. (doi: 10.1093/jnci/djt006) (PMID:23446755) (PMCID:PMC3601953)

This list was generated on Fri Sep 17 05:38:58 2021 BST.
Jump to: Articles
Number of items: 11.

Articles

Horne, G. et al. (2020) A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia, 34(7), pp. 1775-1786. (doi: 10.1038/s41375-019-0700-9) (PMID:31925317) (PMCID:PMC7224085)

Ashton, M. et al. (2018) SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma. Clinical and Translational Radiation Oncology, 8, pp. 45-49. (doi: 10.1016/j.ctro.2017.11.004)

Fulton, B. et al. (2018) PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. Clinical and Translational Radiation Oncology, 8, pp. 12-16. (doi: 10.1016/j.ctro.2017.11.003)

Paul, J. , Kelly, C. , Stobo, J. and Powles, T. (2017) Reply to M. Horiguchi et al. Journal of Clinical Oncology, 35(29), pp. 3373-3374. (doi: 10.1200/jco.2017.74.4292) (PMID:28800270)

Jones, R. J. et al. (2017) Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer. Journal of Clinical Oncology, 35(16), pp. 1770-1777. (doi: 10.1200/JCO.2016.70.7828) (PMID:28402747)

Goranova, T. et al. (2017) Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium. British Journal of Cancer, 116, pp. 1294-1301. (doi: 10.1038/bjc.2017.86) (PMID:28359078) (PMCID:PMC5482731)

MacLeod, N., Kelly, C. , Stobo, J. , McMahon, L., Taggart, D., Fallon, M. and Laird, B. J. (2016) Pain in malignant pleural mesothelioma: a prospective characterization study. Pain Medicine, 17(11), pp. 2119-2126. (doi: 10.1093/pm/pnw061) (PMID:27117437)

Mac Leod, N. et al. (2015) F-18 FDG PET-CT influences target delineation when combined with standard CT-based radiotherapy planning in the palliative setting in malignant pleural mesothelioma; an exploratory study. Reports of Radiotherapy and Oncology, 2(2), e3999. (doi: 10.17795/rro-3999)

MacLeod, N. et al. (2015) Is radiotherapy useful for treating pain in mesothelioma?: a phase II trial. Journal of Thoracic Oncology, 10(6), pp. 944-950. (doi: 10.1097/JTO.0000000000000499) (PMID:25654216)

Gallipoli, P. et al. (2013) Safety and efficacy of pulsed imatinib with or without G-CSFversuscontinuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. British Journal of Haematology, 163(5), pp. 674-676. (doi: 10.1111/bjh.12532)

Chen, M. et al. (2013) Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. Journal of the National Cancer Institute, 105(6), pp. 405-423. (doi: 10.1093/jnci/djt006) (PMID:23446755) (PMCID:PMC3601953)

This list was generated on Fri Sep 17 05:38:58 2021 BST.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • SYSTEMS 2: A randomized Phase II trial of standard versus does escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma
    The London Community Foundation
    2017 - 2018
     
  • A Phase Ib/IIa clinical trial of FAK inhibitor VS6063 in combination with anti-PD1/PDL1 therapy
    Cancer Research UK
    2016 - 2020
     
  • SYSTEMS 2: A randomized Phase II trial of standard versus does escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma
    Beatson Cancer Charity
    2015 - 2018
     
  • SYSTEMS 2: A randomized Phase II trial of standard versus does escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma
    June Hancock Mesothelioma Research Fund
    2014 - 2017